STROKE34 Study Protocol: A Randomized Controlled Phase IIa Trial of Intra-Arterial CD34+ Cells in Acute Ischemic Stroke

• Published in: Frontiers in neurology Vol. 9; p. 302
• Main Authors: Sargento-Freitas, João, Pereira, Anabela, Gomes, André, Amorim, Paula, Matos, Teresa, Cardoso, Carla M. P., Silva, Fernando, Santo, Gustavo Cordeiro, Nunes, César, Galego, Orlando, Carda, José, Branco, João, Lourenço, Víctor, Cunha, Luís, Ferreira, Lino
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 07.05.2018
• Subjects: clinical trial; intervention; ischemic stroke; magnetic resonance imaging; Neuroscience; stem cells; stroke; clinical trial; stem cells; magnetic resonance imaging; intervention; stroke; ischemic stroke
• ISSN: 1664-2295; 1664-2295
• DOI: 10.3389/fneur.2018.00302

Despite the increasing efficacy of recanalization therapies for acute ischemic stroke, a large number of patients are left with long-term functional impairment, devoid of efficacious treatments. CD34+ cells comprise a subset of bone marrow-derived mononuclear cells with the capacity to promote angiogenesis in ischemic lesions and have shown promising results in observational and studies. In this study, we aim to assess the efficacy of an autotransplant of CD34+ cells in acute ischemic stroke. 30 patients will be randomized for a power of 90% and alpha of 0.05 to detect a difference in 3 months infarct volume. We will screen 18-80 years old patients with acute ischemic stroke due to occlusion of a middle cerebral artery (MCA) for randomization. Persistent arterial occlusions, contra-indications to magnetic resonance imaging (MRI), premorbid dependency, or other severe diseases will be excluded. Treatment will involve bone marrow aspiration, selection of CD34+ cells, and their administration intra-arterially in the symptomatic MCA by angiography. Patients will be randomized for treatment at 7 (±2) days, 20 (±5 days) or sham procedure, 10 in each group. The primary outcome will be infarct volume in MRI performed at 3 months. Secondary outcomes will include adverse events and multidimensional functional and neurological measures. STROKE34 is a PROBE design phase IIa clinical trial to assess the efficacy of intra-arterial administration of CD34+ cells 7 and 20 days after acute ischemic stroke. 2017-002456-88.